Cardiovascular Risk in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals.

ABSTRACT:

Background

Chronic hepatitis C (CHC) is associated with hepatic and extrahepatic complications, including cardiovascular disease (CVD). The effects of sustained virological response (SVR) and liver fibrosis on CVD risk are not well established.

Aims

We aim to assess the dynamics of Fibrosis-4 (FIB-4) and Atherosclerotic Cardiovascular Disease 2013 (ASCVD) scores up to three years after direct acting antivirals (DAA) treatment and explore the time-dependent association between the two scores.

Methods

We included consecutive CHC patients treated with DAA and followed up with them for three years. Outcomes were changes from baseline (before DAA) in ASCVD and FIB-4 scores, measured at the end of treatment, 12-, 24-, and 36-months follow-up.

Results

In total, 91 pat

SUBMITTER: Ramadan MS 

PROVIDER: S-EPMC9572655 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature